[A24-50] Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V
Last updated 01.08.2024
Project no.:
A24-50
Commission:
Commission awarded on 30.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Indication:
Adults with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS)
- who have not yet received and who are eligible for erythropoiesis-stimulating agent-based therapy
- without ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoiesis-stimulating agent-based therapy
Result of dossier assessment:
Patients:
- who have not yet received and who are eligible for erythropoiesis-stimulating agent-based therapy: added benefit not proven
- without ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoiesis-stimulating agent-based therapy: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-50_en
| Project no. | Title | Status |
|---|---|---|
| A23-44 | Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-43 | Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-20 | Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G20-15 | Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G20-16 | Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |